Data integrity is key in a pharmaceutical quality system ensuring that products are of the desired quality. Data Integrity is increasingly becoming a critical GMP issue in the Pharmaceutical and Medical Device Industry. ALCOA-plus. A normally used word form for “attributable, legible, contemporaneous, original and accurate”
The descriptor ALCOA has been around since the 1990’s ensuring by regulated industries as a framework for guaranteeing data integrity, and good Documentation practice (GDP). Originally the ALCOA descriptor was used as a straightforward and practical guide by Stan Woolen of us Food and Drug Administration on the North American nation Food and Drug Administration expectations relating to proof of each paper-based, electronic, and hybrid quality systems or records. it’s currently a GMP necessary that each one employee ought to be trained in ALCOA and data Integrity to confirm a corporate culture that values data integrity.
Currently, ALCOA has been expanded on to ALCOA Plus (currently used by the FDA, WHO, PIC/S and GAMP – Data Integrity), this neatly requires all data to have the following qualities:
Alcoa Exclusive Matchmaking Site
| Term | Defination |
| Attribute | Who aquire the data or perfofmed an action and when? |
| Legible | Can you read the data and any entries? |
| Contemporeneous | Data are recorded at the time they are generated or observed |
| Original | A written Printout or observed or certified copy there of |
| Accurate | The term accurate means data are correct, truthful, complete, valid and reliable |
Alcoa was then expanded to Alcoa Plus (Alcoa +), by the addition of a few more concepts which are; Complete, Consistent, Enduring and Available. Over time, the concept of Alcoa plus has been adopted by various industries, as a framework for ensuring that data security and integrity (data protection) is observed and maintained. Exclusive Singapore Matchmaker Premier Matchmaking & Online Dating Support firm for Singles In Singapore, Japan & Other Asia. Find the person right for you to meet in person or via videophone.
- Alcoa (NYSE: AA) is a global industry leader in bauxite, alumina, and aluminum products, and is built on a foundation of strong values and operating excellence dating back more than 130 years to the world-changing discovery that made aluminum an affordable and vital part of modern life.
- Alcoa expects to spend approximately $100 million for site separation and transaction costs, with approximately half being spent in 2021 and the remainder in 2022 and 2023. Credit Suisse Securities (USA) LLC acted as exclusive financial advisor to Alcoa for this transaction and Jones Day served as legal counsel.
- Alcoa Corporation (NYSE: AA) today reported fourth quarter and full-year 2020 results that reflect strong operational performance, the successful execution of multiple cash actions throughout the.
The Newer Alcoa Plus adds a few attribute to the list
Alcoa Exclusive Matchmaking Products
| Term | Defination |
| Complete | All the Data including any repeat or reanalysis performed on the sample, nothing has been deteled (Evidence: Audit trial). |
| Consistent | All elements of the analysis such as the sequence of events follow on and are date or time stamped in the expected sequence. |
| Enduring | Not Recorded on the back of envelops, cigarette packets, sticky notes or the sleeves of a coat but in notrbooks or electronic media in the data systems of instruments |
| Available | Can be accessed for review and audit or inspection over the lifetime of the record |
Why Has Data Integrity Become a Hot Topic?
Alcoa Exclusive Matchmaking Group
Inspectors from regulative bodies inspected the Pharmaceutical business, and that they found that the data wasn’t correct. If a pharmaceutical business produces medicine within the declared parameters, then it’s approved and available within the marketplace for patients. If inspectors realize that the data is changed, then the drug isn’t approved. meaning revenue loss for business and medicines not offered for patients.
Alcoa Exclusive Matchmaking Services
Beginning in 2014 there was a marked increase in warning letters to Indian drug manufacturers addressing data integrity because the Food and Drug Administration uncovered issues throughout regulatory inspections.